NEEDHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will present at the upcoming H.C. Wainwright 25th Annual Global Investment Conference taking place September 11-13, 2023, in New York City.
Format: Corporate Presentation
Date/Time: Monday, September 11, 2023, at 3:00 pm ET
A live webcast of the presentation will be available by selecting Events and Presentations under the News & Events tab in the Investors section on candeltx.com. A replay of the webcast will be archived for up to 90 days following the presentation date.
About Candel Therapeutics
Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel's engineered viruses are designed to induce immunogenic cell death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens while creating a pro-inflammatory microenvironment at the site of injection. This leads to in situ vaccination against the injected tumor and uninjected distant metastases.
The Company has established two clinical stage viral immunotherapy platforms based on novel, genetically modified ...